Is this your firm? Get featured or correct your listing →
At a glance
Frazier Life Sciences appears in 2 funding rounds tracked by ValueAddVC since 2025, leading 1. Its most recent tracked deal was Crystalys Therapeutics' $130M Series B round (Jul 22, 2026). ValueAddVC also tracks 5 funds managed by Frazier Life Sciences.
Strategy
Recent changes
- Oct 14, 2026Oct 14, 2026Frazier Life Sciences II Prices $75M IPO, Lists FLSC Pulse story
- Sep 6, 2026Sep 6, 2026Stages updated: Growth, Buyout frazierhealthcare.com
- Sep 6, 2026Sep 6, 2026Sectors updated: Healthcare, Medical Devices, Pharmaceuticals, Healthcare IT frazierhealthcare.com
- Jul 22, 2026Jul 22, 2026Invested in Crystalys Therapeutics (Series B, $130M) citybiz
- Nov 5, 2025Nov 5, 2025Invested in Braveheart Bio (Series A, $185M) PR Newswire
Earlier changes (5)
- Mar 17, 2025Mar 17, 2025New fund: Frazier Life Sciences Fund XII SEC EDGAR Form D
- Mar 18, 2022Mar 18, 2022New fund: Frazier Life Sciences Fund XI ($960M) SEC EDGAR Form D
- Dec 17, 2019Dec 17, 2019New fund: Frazier Life Sciences Fund X (target $617M) SEC EDGAR Form D
- Nov 1, 2017Nov 1, 2017New fund: Frazier Life Sciences Fund IX ($418.925M) SEC EDGAR Form D
- Oct 29, 2015Oct 29, 2015New fund: Frazier Life Sciences Fund VIII ($262M) SEC EDGAR Form D
Funds
5| Fund | Vintage | Size | Strategy | Source |
|---|---|---|---|---|
| Frazier Life Sciences Fund XII | 2025 | — | Flagship | As of Mar 17, 2025SEC EDGAR Form D |
| Frazier Life Sciences Fund XI | 2022 | $960M | Flagship | As of Mar 18, 2022SEC EDGAR Form D |
| Frazier Life Sciences Fund X | 2019 | target $617M | Flagship | As of Dec 17, 2019SEC EDGAR Form D |
| Frazier Life Sciences Fund IX | 2017 | $418.925M | Flagship | As of Nov 1, 2017SEC EDGAR Form D |
| Frazier Life Sciences Fund VIII | 2015 | $262M | Flagship | As of Oct 29, 2015SEC EDGAR Form D |
Portfolio
3 totalRecent Investment Activity
2Track record: led 1 and participated in 1 of 2 tracked venture rounds · 2 in the last 12 months · led 1 Series B
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Jul 22, 2026 | Crystalys Therapeutics | Series B | Led | $130M | — | Frazier Life SciencesLeadunverified | Pulse story |
| Nov 5, 2025 | Braveheart Bio | Series A | Participated | $185M | — | PR Newswire |
Sector / Stage Activity
Co-Investors
11Similar Firms
overlapping sector, stage or regionLatest Pulse
- Oct 14, 2026Frazier Life Sciences II Prices $75M IPO, Lists FLSCFrazier Life Sciences Acquisition Corp. II priced its $75M IPO at $10 a share, with shares beginning Nasdaq trading under ticker FLSC on October 14.→
- Aug 5, 2026Goldman-Backed Attovia Prices IPO, Lists on NasdaqAttovia Therapeutics priced its IPO at $17/share, raising roughly $212.5M, and began trading on Nasdaq today under ATTO -- another test of whether biotech's IPO window is genuinely reopening.→
- Jul 29, 2026Goldman-Backed Attovia Seeks $212.5M in Biotech IPOAttovia Therapeutics is seeking up to $212.5 million in a US IPO, offering 12.5 million shares at $15-$17 each, backed by Goldman Sachs Alternatives, Deep Track Capital, Frazier Life Sciences, and venBio.→
- Jul 22, 2026Crystalys Raises $130M to Push Gout Drug Through Phase 3Crystalys Therapeutics raised a $130 million Series B led by Frazier Life Sciences to fund global Phase 3 trials of dotinurad, an oral gout drug already approved in five Asian markets, less than a year after a $205 million Series A.→
Frazier Life Sciences FAQ
What is Frazier Life Sciences' latest fund?
Frazier Life Sciences Fund XI, closed at $960M (As of Mar 18, 2022; SEC EDGAR Form D).
How large are Frazier Life Sciences' funds?
Frazier Life Sciences funds Value Add tracks include Frazier Life Sciences Fund XI ($960M, 2022); Frazier Life Sciences Fund IX ($418.925M, 2017); Frazier Life Sciences Fund VIII ($262M, 2015), out of 5 Frazier Life Sciences funds tracked in total.
What companies has Frazier Life Sciences invested in?
Frazier Life Sciences' portfolio includes Braveheart Bio, Attovia Therapeutics, Crystalys Therapeutics.
Who does Frazier Life Sciences co-invest with most?
In the rounds Value Add tracks, Frazier Life Sciences most often invests alongside Andreessen Horowitz (1 shared deal), Deep Track Capital (1 shared deal), EcoR1 Capital (1 shared deal), Enavate Sciences (Patient Square Capital) (1 shared deal), Forbion (1 shared deal).
Sources & methodologyshow
- PR Newswireprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- SEC EDGAR Form Dprimary source1 fact
- citybizValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.